REG - RUA Life Sciences - Change of Registered Office

Rua Life SciencesAnnouncement

30/04/2025 11:45

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250430:nRSd8556Ga&default-theme=true

RNS Number : 8556G  RUA Life Sciences PLC  30 April 2025

 

 

30 April 2025

 

 

 

RUA Life Sciences plc

("RUA Life Sciences", the "Company" or the "Group")

 

Change of registered office

 

RUA Life Sciences, the holding company of a group of medical device businesses
focused on the exploitation of the world's leading long-term implantable
biostable polymer (Elast-EonTM), confirms that it has changed its registered
office and UK head office from 163 Bath Street, Glasgow G2 4SQ to 2 Drummond
Crescent, Riverside Business Park, Irvine, Ayrshire, KA11 5AN with effect
from 30 April 2025.

 

 

For further information contact:

 

RUA Life
Sciences

Bill Brown, Chief
Executive
Tel: +44 (0)1294 317073

Lachlan Smith, Group Chief Financial Officer

 

 

Cavendish Capital Markets Limited

(Nominated Adviser and Broker)
 
              Tel: +44 (0)20 7220 0500

Giles Balleny/Dan Hodkinson (Corporate
Finance)

Charlie Combe (Broking)

Nigel Birks (Healthcare Specialist Sales)

Michael Johnson (Sales)

 

About RUA Life Sciences

RUA Life Sciences plc is the ultimate parent company of the Group, whose
principal activities comprise exploiting the value of its IP & know-how,
medical device contract manufacturing and development of medical devices.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  CROFLFFISAIIVIE